

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma: Primary efficacy and safety analysis of the phase 2 CheckMate 436 study

Armando Santoro,¹ Alison J. Moskowitz,² Silvia Ferrari,³ Carmelo Carlo-Stella,¹ Michelle A. Fanale,⁴ Stephen Francis,⁵ Mariana Sacchi,⁵ Kerry J. Savage⁶

¹Humanitas Clinical and Research Center IRCCS, Humanitas University, Milano, Italy; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; ⁴Seattle Genetics, Bothell, WA, USA; ⁵Bristol Myers Squibb, Princeton, NJ, USA; ⁶Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada



Kerry J. Savage

- Consultancy
 - AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, Merck, Seattle Genetics, Servier
- Research funding
 - Roche (institutional)
- Honoraria
 - AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, Merck, Seattle Genetics
- Steering committee
 - BeiGene



- Mediastinal gray zone lymphoma is an extremely rare form of NHL with a predominance in young men,¹ and with features intermediate between nodular sclerosis cHL and PMBL^{2,3}
- Compared with PMBL, patients with MGZL have inferior survival outcomes after conventional chemotherapy⁴
 - Five-year EFS rates were 62% in MGZL versus 93% in PMBL
 - Five-year OS rates were 74% in MGZL versus 97% in PMBL
- Nivolumab + BV has shown high ORR in adult patients with R/R PMBL and R/R cHL

Nivolumab + BV	ORR, %	CR rate, %
R/R PMBL (CheckMate 436) ⁵	73	37
R/R cHL ⁶	85	67

 In this analysis, the efficacy and safety of nivolumab + BV was evaluated in a separate MGZL cohort in CheckMate 436

BV, brentuximab vedotin; cHL, classical Hodgkin lymphoma; CR, complete response; EFS, event-free survival; MGZL, mediastinal gray zone lymphoma; NHL, non-Hodgkin lymphoma; ORR, objective response rate; OS, overall survival; PMBL, primary mediastinal B-cell lymphoma; R/R, relapsed/refractory.

1. Quintanilla-Martinez L, Fend F. *Haematologica* 2011;96:496-499; 2. Eberle FC, et al. *Haematologica* 2011;96:558-566; 3. Melani C, et al. *N Engl J Med* 2017;377:89-91; 4. Wilson WH, et al. *Blood* 2014;124:1563-1569; 5. Zinzani PL, et al. *J Clin Oncol* 2019;37:3081-3089; 6. Moskowitz AJ, et al. Oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition; December 7-10, 2019; Orlando, FL, USA. Abstract 238.




Key inclusion criteria

- Aged ≥ 18 years
- ECOG PS 0 or 1
- CD30 expression of ≥ 1% in the tumor or tumorinfiltrating lymphocytes
- Measurable MGZL disease
- R/R disease after
 - High-dose chemotherapy+ auto-HCT
 - or

≥ 2 prior multi-agent chemotherapy if auto-HCT ineligible

n = 10^a



Nivolumab 240 mg IV, Q3W^b + BV 1.8 mg/kg^c IV, Q3W^d

Cycles are 21 days until disease progression or unacceptable toxicity

Endpoints

- **Primary**: Investigator-assessed ORR, safety
- Secondary: CR rate, OS, duration of response, PFS

Assessments

- Tumor assessment per Lugano 2014^{e,f}
- Safety evaluated continuously

Follow-up

• Disease progression, safety, OS

^aBased on historical data, a sample size of 10 patients was chosen with the null hypothesis that the true ORR was \leq 10%, to be rejected if 5 or more responses were observed based on an 80% CI; ^bDay 8 of Cycle 1, then Day 1 of every cycle thereafter; ^cPrespecified dose modifications allowed; ^dDay 1 of every cycle. ^ePET/CT on week 6, 12, then Q9W for the subsequent 4 tumor assessment timepoints, and Q12W after the first year; ^fCR is defined as Deauville score 1-3. Auto-HCT, autologous hematopoietic cell transplantation; PET, positron emission tomography; PFS, progression-free survival; PS, performance status; Q3W, every 3 weeks; Q9W,

every 9 weeks; Q12W, every 12 weeks.

Baseline characteristics and patient disposition

	MGZL (n = 10)
Age, median (range), years	35 (25-72)
> 65 years	1 ^a (10)
Male sex	6 (60)
ECOG PS	
0-1	9 (90)
≥ 2	1 (10)
Refractory disease ^b	7 (70)
Median number of prior systemic cancer therapies (range)	2 (1-3)°
Prior auto-HCT	0
Time from completion of most recent prior systemic therapy to study treatment	
< 3 months	8 (80)
3-6 months	1 (10)
> 6 months	1 (10)


- Patients received a median (range) of 7 (5-26) doses of nivolumab and 7 (1-29) doses of BV
- At database lock^d all patients had discontinued treatment due to disease progression (n = 5), maximum clinical benefit (n = 3; all achieved CR and proceeded to allo-HCT), allo-HCT (n = 1), and auto-HCT (n = 1)

Data are n (%) unless stated otherwise. ^aPatient was 72 years old; ^bNo CR following frontline therapy and no CR/PR to any salvage therapy; ^cOne patient received 2 prior regimens but reported as having unknown lines of therapy; ^d8 months after the last patient received the first treatment.

Allo-HCT, allogenic hematopoietic cell transplantation; PR, partial response.

	MGZL (n = 10)
ORR	7 (70)
80% CI, %	45-88
CR	5 (50)
PR	2 (20)
SD	0
PD	2 (20)
Death prior to disease assessment	1 (10)

Data are n (%) unless stated otherwise.




- Median follow-up (range) was 12.4 months (0.1-25.5)
- Time to CR was 1.2-4.8 months and the duration of CR was 1.5+ to 3.2+ months before patients were censored for subsequent therapy
- All patients who achieved CR were bridged to hematopoietic cell transplantation (4 allo- and 1 auto-HCT) and censored (all were alive at database lock)

For tumor reduction, response evaluable patients are those with target lesion(s) assessed at baseline and with all baseline target lesion(s) assessed at \geq 1 on-study timepoint. Best change is based on evaluable target lesion measurements up to progression or start of subsequent therapy.

PD, progressive disease; SD, stable disease.

Overall survival



• Duration of response and PFS could not be estimated reliably due to earlier censoring of patients who received subsequent therapies



	MGZL (n = 10)	
n (%)	Any grade	Grade 3
Any TRAEs	9 (90)	3 ^a (30)
TRAEs occurring in ≥ 2 patients		
Neutropenia	3 (30)	1 (10)
Paresthesia	3 (30)	0
Thrombocytopenia	2 (20)	1 (10)
Anemia	2 (20)	0
Peripheral sensory neuropathy	2 (20)	0
Serious TRAEs		
Febrile neutropenia	1 (10)	1 (10)

- No grade 4 toxicity was observed
- There were 3 deaths, all due to disease progression
- Infusion-related reaction occurred in 1 patient (grade 1)
- Only 1 patient had an immune-mediated AE (grade 2 maculo-papular rash) which resolved without systemic steroids

^aGrade 3 neutropenia, grade 3 thrombocytopenia, and grade 3 febrile neutropenia (n = 1 each).

AE, adverse event; TRAE, treatment-related adverse event.



- Nivolumab + BV demonstrated a high investigator-assessed ORR of 70%, with a 50% CR rate, and a short time to CR (1.2–4.8 months) in patients with R/R MGZL
 - These findings were consistent with those reported with nivolumab + BV in R/R PMBL¹ and R/R cHL^{2,3}
- Safety profile was tolerable and was consistent with previous reports¹⁻³
- The regimen may represent a potential option for bridging to stem cell transplant in patients with chemotherapy-refractory disease

1. Zinzani PL, et al. *J Clin Oncol* 2019;37:3081-3089; 2. Herrara A, et al. *Blood* 2018;131:1183-1194; 3. Moskowitz AJ, et al. Oral presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition; December 7-10, 2019; Orlando, FL, USA. Abstract 238.



- The patients and families who are making the study possible
- The clinical study teams who participated in the trial
- Study drugs provided by Bristol Myers Squibb (Princeton, NJ, USA) and Seattle Genetics, Inc. (Bothell, WA, USA)
- This study was supported by Bristol Myers Squibb, in collaboration with Seattle Genetics
- All authors contributed to and approved the presentation; professional medical writing and editorial assistance were provided by Jane Cheung, Caudex, funded by Bristol Myers Squibb
- For questions please visit: www.globalbmsmedinfo.com



Copies of this presentation obtained through QR Code are for personal use only and may not be reproduced without permission from ASH and the author.

Links are valid for 90 days after the congress presentation date